A detailed history of Black Rock Inc. transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,938,718 shares of YMAB stock, worth $43.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,938,718
Previous 2,857,257 2.85%
Holding current value
$43.5 Million
Previous $46.5 Million 23.59%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$11.6 - $17.25 $944,947 - $1.41 Million
81,461 Added 2.85%
2,938,718 $35.5 Million
Q1 2024

May 10, 2024

SELL
$6.57 - $18.69 $393,037 - $1.12 Million
-59,823 Reduced 2.05%
2,857,257 $46.5 Million
Q4 2023

Feb 13, 2024

BUY
$4.88 - $7.42 $2.17 Million - $3.29 Million
443,724 Added 17.94%
2,917,080 $19.9 Million
Q3 2023

Nov 13, 2023

SELL
$4.86 - $7.23 $283,935 - $422,398
-58,423 Reduced 2.31%
2,473,356 $13.5 Million
Q2 2023

Aug 11, 2023

BUY
$5.68 - $10.34 $969,496 - $1.76 Million
170,686 Added 7.23%
2,531,779 $17.2 Million
Q1 2023

May 12, 2023

SELL
$2.83 - $5.11 $616,042 - $1.11 Million
-217,683 Reduced 8.44%
2,361,093 $11.8 Million
Q4 2022

Feb 13, 2023

SELL
$3.0 - $15.17 $955,854 - $4.83 Million
-318,618 Reduced 11.0%
2,578,776 $12.6 Million
Q3 2022

Nov 14, 2022

SELL
$13.96 - $19.67 $1.1 Million - $1.55 Million
-78,827 Reduced 2.65%
2,897,394 $41.8 Million
Q2 2022

Aug 12, 2022

BUY
$8.22 - $15.13 $255,863 - $470,951
31,127 Added 1.06%
2,976,221 $45 Million
Q1 2022

May 12, 2022

BUY
$6.55 - $17.42 $1.16 Million - $3.1 Million
177,734 Added 6.42%
2,945,094 $35 Million
Q4 2021

Feb 10, 2022

BUY
$15.51 - $29.31 $473,055 - $893,955
30,500 Added 1.11%
2,767,360 $44.9 Million
Q3 2021

Nov 09, 2021

BUY
$27.47 - $37.31 $911,152 - $1.24 Million
33,169 Added 1.23%
2,736,860 $78.1 Million
Q2 2021

Aug 11, 2021

BUY
$25.45 - $37.64 $68.8 Million - $102 Million
2,703,691 New
2,703,691 $91.4 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $647M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.